Article Text

Download PDFPDF
Absence of germline mutations in MINPP1, a phosphatase encoding gene centromeric of PTEN, in patients with Cowden and Bannayan-Riley- Ruvalcaba syndrome without germlinePTEN mutations
  1. PATRICIA M DAHIA*,
  2. OLIVER GIMM*,
  3. HONGOBO CHI,
  4. DEBBIE J MARSH*§,
  5. PAUL R REYNOLDS,
  6. CHARIS ENG*
  1. *Clinical Cancer Genetics and Human Cancer Genetics Programs, Ohio State University Comprehensive Cancer Center, 420 W 12th Avenue, Room 690C MRF, Columbus, OH 43210, USA
  2. †Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
  3. ‡Department of Orthopaedics, University of Rochester School of Medicine, Rochester, NY, USA
  4. ¶CRC Human Cancer Genetics Research Group, University of Cambridge, Cambridge, UK
  1. Professor Eng, eng-1{at}medctr.osu.edu

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Editor—Germline mutations in the dual specificity phosphatase genePTEN (also known as MMAC1 orTEP1) have been associated with susceptibility to two related hamartomatous disorders, Cowden syndrome (CS, MIM 158350) and Bannayan-Riley-Ruvalcaba syndrome (BRR, MIM 153480).1 2It has recently been established that PTEN functions as a 3-phosphatase towards phospholipid substrates in the phosphatidylinositol 3-kinase (PI-3 kinase) pathway.3 Lack of PTEN results in the accumulation of phosphatidylinositol-(3,4,5)-P3, which is required for activation of protein kinase B (PKB)/Akt, a downstream target of PI3-kinase and a known cell survival factor.4-8

While up to 81% of CS and approximately 60% of BRR cases have detectable PTEN germline mutations, no mutations in the coding region or exon-intron boundaries of PTEN have been found in the remaining affected subjects.2 9-13Informative PTEN mutation negative families have been shown to be linked to the 10q23 region, where PTENlies,2 14 although recently there has been a report of two CS families in which linkage to 10q23 has been excluded.9 This has raised the possibility that either a regulatory region of the PTEN gene not included in previous studies, such as the promoter region, or another, closely located gene might be responsible for the CS and BRR cases in which noPTEN mutation has been found. The first alternative is unlikely to represent the majority of such cases, as no evidence ofPTEN transcriptional silencing has been detected in …

View Full Text

Footnotes

  • § Present address: Cancer Genetics Laboratory, Kolling Institute for Medical Research, Department of Medicine, University of Sydney, St Leonards, NSW, Australia